

Pregabalin Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/P642DD3E3F2CEN.html>

Date: April 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: P642DD3E3F2CEN

Abstracts

The Global Pregabalin Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 5.1% to reach USD 3 billion by 2034. This consistent upward trajectory reflects the rising demand for effective treatments targeting chronic neurological conditions, including neuropathic pain, epilepsy, and generalized anxiety disorder (GAD). Pregabalin has become a cornerstone in the global pharmaceutical landscape due to its dual action as an anticonvulsant and analgesic. Healthcare professionals are increasingly prescribing it as a safer alternative to opioids, especially in long-term pain management. Its growing acceptance across hospitals, retail pharmacies, and online platforms is a testament to its therapeutic reliability. In both developed and emerging regions, an expanding patient base, rising health awareness, and improvements in healthcare access are accelerating market penetration. Increased awareness around chronic pain conditions, combined with a global shift toward non-opioid treatment options, continues to create lucrative growth opportunities for manufacturers and suppliers worldwide. Additionally, favorable regulatory frameworks and growing investments in the healthcare sector are pushing pharmaceutical companies to strengthen their presence in this space, fueling innovation and commercialization strategies.

The pregabalin market is segmented into two primary formulations: tablets and capsules and oral solutions. Tablets and capsules remain the preferred choice among patients and healthcare providers, primarily because of their ease of use and consistent dosing. This segment is projected to grow at a CAGR of 5.1%, reaching USD 2.3 billion by 2034. The convenience offered by solid dosage forms is especially important for patients managing chronic conditions, as tablets and capsules are easier to store, transport, and consume compared to liquid formulations. Moreover, pharmaceutical companies continue to expand their product lines with varied dosage strengths,

enabling more personalized treatment regimens and enhancing patient adherence.

In terms of application, the pregabalin market is categorized into epilepsy, neuropathic pain, generalized anxiety disorder, and other uses. Among these, the neuropathic pain segment is anticipated to record the fastest growth at a CAGR of 5.2%, reaching USD 1.6 billion by 2034. Rising incidences of diabetes, cancer, and aging-related nerve damage are fueling the demand for effective neuropathic pain therapies. Healthcare providers are prioritizing early diagnosis and timely intervention, while patients increasingly seek sustainable alternatives to traditional pain relief methods. As a result, pregabalin continues to gain momentum as a first-line treatment option in neurology.

The U.S. Pregabalin Market was valued at USD 754 million in 2024 and is expected to maintain strong growth momentum. A surge in chronic neuropathic disorders, coupled with heightened awareness about the risks associated with opioid dependency, is driving this trend. Pregabalin's positioning as a non-opioid pain reliever has made it a preferred choice among physicians and patients alike, particularly in managing conditions like diabetic neuropathy and post-herpetic neuralgia.

Prominent players shaping the global pregabalin market landscape include Zydus Lifesciences, Cipla, Teva Pharmaceutical Industries, Aurobindo Pharma, Amneal Pharmaceuticals, Apotex, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Novartis, Alkem Laboratories, Lupin, and Viartis. These companies are consistently investing in research and development to enhance pregabalin formulations. Strategic collaborations, acquisitions, and expanded production capacities are helping industry leaders meet rising global demand while staying competitive.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Rising prevalence of neuropathic pain and epilepsy
 - 3.2.1.2 Growing geriatric population
 - 3.2.1.3 Expanding approval for new indications
 - 3.2.1.4 Increasing availability of generic versions
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 Stringent regulatory requirements
 - 3.2.2.2 Risk of misuse and addiction
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY FORMULATION, 2021 - 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Tablets and capsules
- 5.3 Oral solution

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 - 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Neuropathic pain
- 6.3 Epilepsy
- 6.4 Generalized anxiety disorder
- 6.5 Other applications

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 - 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 E-commerce

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 - 2034 (\$ MN)

- 8.1 Key trends
- 8.2 North America

- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
 - 8.3.1 Germany
 - 8.3.2 UK
 - 8.3.3 France
 - 8.3.4 Spain
 - 8.3.5 Italy
 - 8.3.6 Netherlands
- 8.4 Asia Pacific
 - 8.4.1 China
 - 8.4.2 Japan
 - 8.4.3 India
 - 8.4.4 Australia
 - 8.4.5 South Korea
- 8.5 Latin America
 - 8.5.1 Brazil
 - 8.5.2 Mexico
 - 8.5.3 Argentina
- 8.6 Middle East and Africa
 - 8.6.1 South Africa
 - 8.6.2 Saudi Arabia
 - 8.6.3 UAE

CHAPTER 9 COMPANY PROFILES

- 9.1 Alkem Laboratories
- 9.2 Amneal Pharmaceuticals
- 9.3 Apotex
- 9.4 Aurobindo Pharma
- 9.5 Cipla
- 9.6 Dr. Reddy's Laboratories
- 9.7 Hikma Pharmaceuticals
- 9.8 Lupin
- 9.9 Novartis
- 9.10 Pfizer
- 9.11 Sun Pharmaceutical Industries
- 9.12 Teva Pharmaceutical Industries
- 9.13 Torrent Pharmaceuticals

9.14 Viatris

9.15 Zydus Lifesciences

I would like to order

Product name: Pregabalin Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/P642DD3E3F2CEN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P642DD3E3F2CEN.html>